The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.

Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by ...

The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...

Tandem Diabetes Care, Inc. TNDM recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is ...

Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...

Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with U-100 insulin only. WARNING: Control-IQ technology should not be used by anyone under the age ...

Please provide your email address to receive an email when new articles are posted on . Managing glucose levels during pregnancy in women with type 1 diabetes is important for the mother and child.